[{"address1": "345 Park Avenue South", "address2": "6th Floor", "city": "New York", "state": "NY", "zip": "10010", "country": "United States", "phone": "212 547 9879", "website": "https://www.lexeotx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company also develops LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has license agreement with Cornell University to conduct of the Phase 1/2 clinical trial of LX1001, as well as support the development of LX1004 program; research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. The company was founded in 2017 and is headquartered in New York, New York.", "fullTimeEmployees": 61, "companyOfficers": [{"maxAge": 1, "name": "Mr. R. Nolan Townsend M.B.A.", "age": 45, "title": "CEO & Director", "yearBorn": 1980, "fiscalYear": 2024, "totalPay": 3741748, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ronald G. Crystal M.D.", "title": "Co-Founder, Chief Scientific Advisor & Member of Scientific Advisory Board", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Louis  Tamayo", "age": 49, "title": "CFO & Principal Accounting Officer", "yearBorn": 1976, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jenny R. Robertson J.D.", "age": 50, "title": "Chief Legal Officer", "yearBorn": 1975, "fiscalYear": 2024, "totalPay": 617900, "exercisedValue": 0, "unexercisedValue": 94692}, {"maxAge": 1, "name": "Mr. Jordan M. Baumhardt Ph.D.", "title": "Vice President of Corporate Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sandi See Tai M.D.", "age": 54, "title": "Chief Development Officer", "yearBorn": 1971, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Leslie  DiRisio", "title": "Senior Vice President of Development Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 6, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1768176000, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 7.57, "open": 7.5, "dayLow": 7.115, "dayHigh": 7.64, "regularMarketPreviousClose": 7.57, "regularMarketOpen": 7.5, "regularMarketDayLow": 7.115, "regularMarketDayHigh": 7.64, "payoutRatio": 0.0, "beta": 1.766, "forwardPE": -5.309126, "volume": 842259, "regularMarketVolume": 842259, "averageVolume": 1366493, "averageVolume10days": 833930, "averageDailyVolume10Day": 833930, "bid": 7.37, "ask": 7.45, "bidSize": 1, "askSize": 1, "marketCap": 540836096, "fiftyTwoWeekLow": 1.45, "fiftyTwoWeekHigh": 10.99, "allTimeHigh": 22.33, "allTimeLow": 1.45, "fiftyDayAverage": 9.0532, "twoHundredDayAverage": 6.1898, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 426529088, "profitMargins": 0.0, "floatShares": 48178205, "sharesOutstanding": 72987327, "sharesShort": 11456768, "sharesShortPriorMonth": 7101931, "sharesShortPreviousMonthDate": 1765756800, "dateShortInterest": 1768435200, "sharesPercentSharesOut": 0.157, "heldPercentInsiders": 0.00424, "heldPercentInstitutions": 0.90993, "shortRatio": 6.45, "shortPercentOfFloat": 0.16790001, "impliedSharesOutstanding": 72987327, "bookValue": 2.2, "priceToBook": 3.3681817, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -104966000, "trailingEps": -2.5, "forwardEps": -1.39571, "enterpriseToEbitda": -3.777, "52WeekChange": 0.3351351, "SandP52WeekChange": 0.1575526, "quoteType": "EQUITY", "currentPrice": 7.41, "targetHighPrice": 30.0, "targetLowPrice": 10.0, "targetMeanPrice": 19.63636, "targetMedianPrice": 19.0, "recommendationKey": "none", "numberOfAnalystOpinions": 11, "totalCash": 122764000, "totalCashPerShare": 1.682, "ebitda": -112933000, "totalDebt": 8457000, "quickRatio": 7.108, "currentRatio": 7.399, "debtToEquity": 6.999, "returnOnAssets": -0.44665, "returnOnEquity": -0.80694, "grossProfits": -65953000, "freeCashflow": -68584496, "operatingCashflow": -106808000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "LXEO", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "corporateActions": [], "postMarketTime": 1769811927, "regularMarketTime": 1769806802, "regularMarketChangePercent": -2.1136105, "regularMarketPrice": 7.41, "exchange": "NGM", "messageBoardId": "finmb_625814286", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1699018200000, "postMarketChangePercent": 0.0, "postMarketPrice": 7.41, "postMarketChange": 0.0, "regularMarketChange": -0.16000032, "regularMarketDayRange": "7.115 - 7.64", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 1366493, "fiftyTwoWeekLowChange": 5.96, "fiftyTwoWeekLowChangePercent": 4.110345, "fiftyTwoWeekRange": "1.45 - 10.99", "fiftyTwoWeekHighChange": -3.58, "fiftyTwoWeekHighChangePercent": -0.32575068, "fiftyTwoWeekChangePercent": 33.51351, "earningsTimestamp": 1762349400, "earningsTimestampStart": 1762349400, "earningsTimestampEnd": 1762349400, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -2.5, "epsForward": -1.39571, "epsCurrentYear": -1.9225, "priceEpsCurrentYear": -3.8543563, "fiftyDayAverageChange": -1.6431999, "fiftyDayAverageChangePercent": -0.18150488, "twoHundredDayAverageChange": 1.2202001, "twoHundredDayAverageChangePercent": 0.19713078, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2023-11-03", "cryptoTradeable": false, "shortName": "Lexeo Therapeutics, Inc.", "longName": "Lexeo Therapeutics, Inc.", "marketState": "CLOSED", "displayName": "Lexeo Therapeutics", "trailingPegRatio": null, "__fetch_time": "2026-01-31"}]